MARKET

AGEN

AGEN

Agenus
NASDAQ
3.930
+0.180
+4.80%
Opening 12:47 01/09 EST
OPEN
3.800
PREV CLOSE
3.750
HIGH
4.000
LOW
3.800
VOLUME
460.98K
TURNOVER
--
52 WEEK HIGH
7.34
52 WEEK LOW
1.380
MARKET CAP
133.65M
P/E (TTM)
-1.8788
1D
5D
1M
3M
1Y
5Y
1D
Agenus amends Ligand agreement, modifies warrant holder rights
TipRanks · 20h ago
Agenus (AGEN) Q1 2025 Earnings Call Transcript
NASDAQ · 3d ago
Weekly Report: what happened at AGEN last week (1229-0102)?
Weekly Report · 4d ago
Weekly Report: what happened at AGEN last week (1222-1226)?
Weekly Report · 12/29/2025 10:34
Agenus publishes C-800-01 trial data in The Journal for ImmunoTherapy of Cancer
TipRanks · 12/23/2025 13:20
Agenus Reports Promising Results for Botensilimab and Balstilimab in Refractory Ovarian Cancer Trial
Reuters · 12/23/2025 13:05
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
Barchart · 12/23/2025 07:05
Weekly Report: what happened at AGEN last week (1215-1219)?
Weekly Report · 12/22/2025 10:34
More
About AGEN
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Webull offers Agenus Inc stock information, including NASDAQ: AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.